Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Nyxoah SA (NYXH : NSDQ)
 
 • Company Description   
Nyxoah SA is a medical technology company. It focused on the development and commercialization of solutions to treat Obstructive Sleep Apnea. Nyxoah SA is based in Belgium.

Number of Employees: 184

 
 • Price / Volume Information   
Yesterday's Closing Price: $7.77 Daily Weekly Monthly
20 Day Moving Average: 33,591 shares
Shares Outstanding: 34.06 (millions)
Market Capitalization: $264.65 (millions)
Beta: 1.62
52 Week High: $11.87
52 Week Low: $5.55
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 1.30% -3.20%
12 Week 26.34% 7.91%
Year To Date -2.88% -9.03%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
RUE EDOUARD BELIN 12
-
MONT-SAINT-GUIBERT,C9 1435
BEL
ph: 321-022-2355
fax: 321-045-9075
ir@nyxoah.com http://www.nyxoah.com
 
 • General Corporate Information   
Officers
Olivier Taelman - Chief Executive Officer
Robelga SRL - Chairman
John Landry - Chief Financial Officer
Kevin Rakin - Director
Pierre Gianello - Director

Peer Information
Nyxoah SA (HLIS)
Nyxoah SA (AZTA)
Nyxoah SA (APYI)
Nyxoah SA (RNVA)
Nyxoah SA (HMSY)
Nyxoah SA (LRSI)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MEDICAL INFO SYS
Sector: Medical
CUSIP: B6S7WD106
SIC: 3841
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
Share - Related Items
Shares Outstanding: 34.06
Most Recent Split Date: (:1)
Beta: 1.62
Market Capitalization: $264.65 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.54 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.41 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.71
Price/Cash Flow: -
Price / Sales: 56.46
EPS Growth
vs. Year Ago Period: -40.00%
vs. Previous Quarter: -28.57%
Sales Growth
vs. Year Ago Period: -15.61%
vs. Previous Quarter: -16.93%
ROE
06/30/25 - -
03/31/25 - -63.37
12/31/24 - -54.60
ROA
06/30/25 - -
03/31/25 - -46.67
12/31/24 - -41.28
Current Ratio
06/30/25 - -
03/31/25 - 3.59
12/31/24 - 4.56
Quick Ratio
06/30/25 - -
03/31/25 - 3.35
12/31/24 - 4.34
Operating Margin
06/30/25 - -
03/31/25 - -1,571.39
12/31/24 - -1,287.92
Net Margin
06/30/25 - -
03/31/25 - -1,571.39
12/31/24 - -1,287.92
Pre-Tax Margin
06/30/25 - -
03/31/25 - -1,529.93
12/31/24 - -1,248.26
Book Value
06/30/25 - -
03/31/25 - 2.87
12/31/24 - 3.60
Inventory Turnover
06/30/25 - -
03/31/25 - 0.30
12/31/24 - 0.33
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.22
12/31/24 - 0.19
Debt-to-Capital
06/30/25 - -
03/31/25 - 18.33
12/31/24 - 15.82
 

Powered by Zacks Investment Research ©